Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. - Wikidata - wikimedia - TriplyDB

Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial.

Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial.

http://www.wikidata.org/entity/Q34436090

about

Elusive roles for reactive astrocytes in neurodegenerative diseases Designing Novel Nanoformulations Targeting Glutamate Transporter Excitatory Amino Acid Transporter 2: Implications in Treating Drug Addiction.Pre-morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosis Preclinical Rodent Toxicity Studies for Long Term Use of Ceftriaxone Intraspinal stem cell transplantation for amyotrophic lateral sclerosis Transplantation of spinal cord-derived neural stem cells for ALS: Analysis of phase 1 and 2 trials Patient-reported problematic symptoms in an ALS treatment trial.Motor neuron disease in 2014. Biomarkers for ALS--in search of the Promised Land Motor neuron disease-frontotemporal dementia: a clinical continuum.FTD and ALS--translating mouse studies into clinical trials.GLAST But Not Least--Distribution, Function, Genetics and Epigenetics of L-Glutamate Transport in Brain--Focus on GLAST/EAAT1.Glutamate transporter EAAT2: regulation, function, and potential as a therapeutic target for neurological and psychiatric disease.A retrospective review of the progress in amyotrophic lateral sclerosis drug discovery over the last decade and a look at the latest strategies.Causal inference methods to study gastric tube use in amyotrophic lateral sclerosis.Neurological Adverse Effects Attributable to β-Lactam Antibiotics: A Literature Review.Astroglial Scarring and Seizures: A Cell Biological Perspective on Epilepsy.Establishment and characterization of a new conditionally immortalized human astrocyte cell line.Transcriptional Regulation of Glutamate Transporters: From Extracellular Signals to Transcription Factors.Potential new complication in drug therapy development for amyotrophic lateral sclerosis.Strength Testing in Motor Neuron Diseases.Fixed dynamometry is more sensitive than vital capacity or ALS rating scale.Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis.Astroglial glutamate transporters in the brain: Regulating neurotransmitter homeostasis and synaptic transmission.Astroglia as a cellular target for neuroprotection and treatment of neuro-psychiatric disorders.An astroglial basis of major depressive disorder? An overview.Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial.The MITOS system predicts long-term survival in amyotrophic lateral sclerosis.Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutations Blood hemoglobin A1c levels and amyotrophic lateral sclerosis survival.Quantitative strength testing in ALS clinical trials.Pharmacologic inhibition of Hsp90 to prevent GLT-1 degradation as an effective therapy for epilepsy.Motoneuron Disease: Clinical.How good are publicly available web services that predict bioactivity profiles for drug repurposing?Are patients with amyotrophic lateral sclerosis at risk of a therapeutic misconception?A computational combinatorial approach identifies a protein inhibitor of superoxide dismutase 1 misfolding, aggregation, and cytotoxicity.An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe.Exploring the diagnosis delay and ALS functional impairment at diagnosis as relevant criteria for clinical trial enrolment.Pharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populations.Upregulation of Vesicular Glutamate Transporter 2 and STAT3 Activation in the Spinal Cord of Mice Receiving 3,3'-Iminodipropionitrile.Mutation of the caspase-3 cleavage site in the astroglial glutamate transporter EAAT2 delays disease progression and extends lifespan in the SOD1-G93A mouse model of ALS.

P2860

Q26797399-3FC8929C-3EC0-4A7A-AEFB-B067804F1B73 Q34504098-823DE888-C013-430A-83CA-9FDDFCFD620A Q35952241-B3B6507F-4CFB-4BA3-BBCE-02E5F4039ECD Q36389087-39DD697F-ED98-4E92-95D5-5259F04527C9 Q36679757-6D363173-37A1-416A-A92E-38CE6FF24B87 Q37158966-3A3B66AC-03C1-412D-9769-7802567BADDB Q37164599-ECC17AA6-4932-4848-9CA6-C0E888BCD9B7 Q37532592-822D49C2-D338-4AA1-AEB1-615A165BC33D Q38417288-BC0B6526-2FE0-4671-A90E-12154DE29ABC Q38457811-A8EE401A-4B25-46A7-BFAE-644F1DC6D62C Q38478361-BB30C0A4-673A-4B3C-B0E4-1AB629201538 Q38512084-C6ADDDF2-6576-4E4C-AB38-64DCA850A962 Q38573829-C2A75CC0-B6AE-4093-9EBD-59A4CA396047 Q38597213-B0FE04D1-9E84-4B56-899C-770AEE5CB587 Q38654209-1A2E2CC7-1829-4EDF-983B-52FEC3FF4D0B Q38818777-787D5B98-4C0B-4F7F-AF22-037EF8D05AB0 Q38835686-295EAA33-940C-4485-9C33-E1AB90B096C9 Q38861849-D416F4AB-98E6-447C-ADAC-DECB92C06241 Q38881707-55F5D6D5-4756-4142-A5E4-4228F1C14AD8 Q38947721-E7D9DAA1-4B38-4889-90F1-325C95B2158C Q39000702-AA0388D8-5CA4-4A5E-A49B-BACED9994806 Q39033841-E929D112-483A-4641-8874-ADB61DD2BBC3 Q39115057-59328CCD-9D04-4081-AA48-CA231654EFA5 Q39181656-A12CB95A-BFFE-46DE-B5DC-E960485C49B3 Q39186841-7BE96209-7162-4E61-BDFA-17F2BBB807C6 Q41009555-7877B7BD-1D2F-4B06-9645-E55A71992348 Q41052218-A3C3E155-F1FE-4C9E-9D98-8B2AAB5CF285 Q41066718-8192E3F2-CCA4-4D95-BA98-880C7B35A5D7 Q41693587-E0B51929-6B24-4FEF-93B4-E1F6AF98FBBF Q42175195-702EFD73-0C27-4858-BCF7-D48282544C8F Q42323492-75409069-50FF-4C0F-9292-90EB0D22AAE0 Q45869420-CD2C5066-0ED8-48A6-B0F5-E7F5D655D6E4 Q45943515-5FC8AEEF-88CF-49C7-8572-D0357D593F78 Q47443859-FAD1261C-44CA-4CF3-96A7-2078BA90A7C5 Q47741777-5DAEF5D8-E723-4838-8B9D-63389AF85695 Q47782678-6E51CDC6-3523-4F1D-A597-94CA27EB9368 Q47815494-56220735-8E16-494E-85FA-D94AB7980943 Q48033726-251A1587-2F08-413A-BC41-54EB2DF37EAD Q48263387-90CAF2E0-D386-4A04-97E1-FAE879A27BD8 Q50773821-0680F007-3DE7-44A1-95A7-9DE29368A9AD

P2860

Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial.

http://www.wikidata.org/entity/Q34436090

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Safety and efficacy of ceftria ...... ind, placebo-controlled trial.

@ast

Safety and efficacy of ceftria ...... ind, placebo-controlled trial.

@en

Safety and efficacy of ceftria ...... ind, placebo-controlled trial.

@nl

type

label

Safety and efficacy of ceftria ...... ind, placebo-controlled trial.

@ast

Safety and efficacy of ceftria ...... ind, placebo-controlled trial.

@en

Safety and efficacy of ceftria ...... ind, placebo-controlled trial.

@nl

prefLabel

Safety and efficacy of ceftria ...... ind, placebo-controlled trial.

@ast

Safety and efficacy of ceftria ...... ind, placebo-controlled trial.

@en

Safety and efficacy of ceftria ...... ind, placebo-controlled trial.

@nl

P1433

Q34436090-0A9359C2-2751-4208-BEB3-A2CEF7864845

P1476

Q34436090-330AE135-1D7B-4529-ACC1-75C45E61FF6F

P2093

Q34436090-0475E310-6982-4E73-AF99-FF4297C3538B

Q34436090-09D606BF-79A9-4FE8-A94C-421C45363F77

Q34436090-302F6F1D-578F-44C8-B34D-243590D71D9C

Q34436090-33B9EB44-2B19-4FD1-B6B9-28B02810A40E

Q34436090-463B94B6-64D7-4652-AC1B-2832D29FA115

Q34436090-48EC8BCE-A7C4-496C-B200-6AE311A4C15B

Q34436090-5389E5BD-D0B7-43E7-8253-1C9200F7C3F5

Q34436090-581979F1-4A8A-4DE0-BE6F-9BA920A7FD7B

Q34436090-73BFDD39-ACE0-4215-9AB3-241D9AE44974

Q34436090-7757DF9B-56C1-4192-9FFE-2A2C83E9877D

P2860

Q34436090-012F507C-68CB-450B-9A8C-AD479C1DA291

Q34436090-03167112-A4F4-4199-8460-A2881A83028C

Q34436090-05505EDF-B1BD-43D7-8322-F2ABC2E61C93

Q34436090-0607E8EF-77B0-4BBD-9506-32D486A78A73

Q34436090-0CBC1F47-C9D9-484D-BF07-53E7814F51B8

Q34436090-0EA170FC-D917-4DEA-883E-3AFD7366C790

Q34436090-0FE2164B-52CC-4B7D-9A1C-E22DC3F169DE

Q34436090-10C1A68E-743C-45AB-BF10-CC0BEEE492B3

Q34436090-2646E8BB-4D7D-44E0-8AF9-569518045077

Q34436090-2D50F1F3-5F65-4A26-B4B5-C4C11FE68DAB

P304

Q34436090-A1F3C695-0093-4D29-A408-2981ACF21976

P31

Q34436090-1E65DCF5-C049-4508-BC7C-5F9E71410393

P356

Q34436090-32FD42A5-DEEB-40DF-BA2C-BD4FF5AAC123

P433

Q34436090-DFE02228-DE56-44B1-B975-1326CF22C718

P478

Q34436090-5A42E49B-7A3C-4EE3-968E-2EE496C5803D

P50

Q34436090-2BF45D64-4E9E-492B-AC1F-80E5A1A09DAD

P577

Q34436090-C4A77926-77B2-45A4-A2C8-8A283B931E06

P698

Q34436090-E4C169C8-5B2D-43EF-8661-AEA93F68C8BB

P921

Q34436090-34E9D5FD-9C4B-4292-986D-345D9FC3C682

Q34436090-8247B9EB-0591-4281-BCA1-CC87ED30A451

P932

Q34436090-E48DE867-24DB-4FA9-BEF8-D39E170D66CF

P356

S1474-4422(14)70222-4

P1433

Lancet Neurology

P1476

Safety and efficacy of ceftria ...... ind, placebo-controlled trial.

@en

P2093

Alexander Sherman

http://www.w3.org/2001/XMLSchema#string

Amy Shui

http://www.w3.org/2001/XMLSchema#string

Benjamin Brooks

http://www.w3.org/2001/XMLSchema#string

Ceftriaxone Study Investigators

http://www.w3.org/2001/XMLSchema#string

David J Greenblatt

http://www.w3.org/2001/XMLSchema#string

David Schoenfeld

http://www.w3.org/2001/XMLSchema#string

Donna Felsenstein

http://www.w3.org/2001/XMLSchema#string

Douglas Hayden

http://www.w3.org/2001/XMLSchema#string

Ericka Simpson

http://www.w3.org/2001/XMLSchema#string

Hong Yu

http://www.w3.org/2001/XMLSchema#string

P2860

Subcutaneous IGF-1 is not beneficial in 2-year ALS trial

Borrelia burgdorferi detected by culture and PCR in clinical relapse of disseminated Lyme borreliosis

From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS

Phase II/III randomized trial of TCH346 in patients with ALS

Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis

El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis

Shared parameter models for the joint analysis of longitudinal data and event times.

A beta-lactam antibiotic dampens excitotoxic inflammatory CNS damage in a mouse model of multiple sclerosis.

Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis.

P304

1083-1091

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1474-4422(14)70222-4

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Merit E Cudkowicz

P577

2014-10-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25297012

http://www.w3.org/2001/XMLSchema#string

P921

amyotrophic lateral sclerosis

P932

4216315

http://www.w3.org/2001/XMLSchema#string